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In most protocols of peptide-based vaccination, no consideration has been paid to whether or not peptide-specific cytotoxic T-
lymphocyte (CTL) precursors are pre-existent in cancer patients. Initiation of immune boosting through vaccination is better than that
of immune priming to induce prompt and strong immunity. In this study, 10 human histocompatibility leukocyte antigen-A24
þ
patients with advanced colorectal carcinomas were treated with up to four peptides that had been positive for pre-vaccination
measurement of peptide-specific CTL precursors in the circulation (CTL precursor-oriented peptide vaccine). No severe adverse
effect was observed, although local pain and fever of grade I or II were observed. Post-vaccination peripheral blood mononuclear cells
(PBMCs) from five patients demonstrated an increased peptide-specific immune response to the peptides. Increased CTL response
to cancer cells was detected in post-vaccination PBMCs of five patients. Antipeptide immunoglobulin G became detectable in post-
vaccination sera of seven patients. Three patients developed a positive delayed-type hypersensitivity response to at least one of the
peptides administrated. One patient was found to have a partial response; another had a stable disease, sustained through 6 months.
These results encourage further development of CTL precursor-oriented vaccine for colorectal cancer patients.
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Recent advances in molecular biology and cellular immunology
have resulted in identification of various antigens and epitopes
recognised by human histocompatibility leukocyte antigen (HLA)-
class-I-restricted cytotoxic T lymphocytes (CTLs) from various
cancers (Bruggen et al, 1991; Brichard et al, 1993; Kawakami et al,
1994a,b Fisk et al, 1995; Peoples et al, 1995; Robbins et al, 1996;
Correale et al, 1997; Correale et al, 1998). Many clinical trials of
peptide-based immunotherapy have shown an increased immune
response to the vaccinated peptides (Rosenberg et al, 1998;
Marchand et al, 1999; Jager et al, 2000; Gajewski et al, 2001;
Gjertsen et al, 2001; Lau et al, 2001; Valmori et al, 2001). However,
these initial clinical studies have produced few clinical responses
in the various types of cancer treated including melanoma and
colorectal cancer (Finn and Lotze, 2001; Miyagi et al, 2001;
Sadanaga et al, 2001). This failure could be in part due to the
insufficient and late stages of CTL induction by the current
regimen, in which pre-vaccination screening of suitable peptides
for each patient among a large number of candidate peptides is not
conducted. As a result, vaccination in the present study began with
immune priming. This standard regimen could be effective in
preventing infectious disease. However, the main goal of a cancer
vaccine is treatment of malignant disease. The time-lag necessary
for priming of an antitumour response should be seriously
considered, as the expected survival of most advanced cancer
patients under these regimens is 3–9 months (Cole and Rodu,
2001; Miyagi et al, 2001). Therefore, the development of a new
regimen of therapeutic vaccine is needed (Finn and Lotze, 2001).
One regimen might include pre-vaccination measurement of
peptide-specific CTL precursors in the circulation, followed by
vaccination of only CTL-reactive peptides (CTL precursor-oriented
vaccine). We have previously reported 14 vaccine candidate
peptides that can induce HLA-A24-restriced and tumour-specific
CTL in cancer patients (Gomi et al, 1999; Kikuchi et al, 1999; Yang
et al, 1999; Harashima et al, 2000; Kawano et al, 2000; Nakao et al,
2000; Nishizaka et al, 2000). We have also shown that most cancer
patients have peptide-specific CTL precursors for some of these
peptides, and that peripheral blood mononuclear cells (PBMCs)
stimulated with positive peptides show HLA-class-I-restricted and
tumour-specific cytotoxicity (Hida et al, 2002; Maeda et al, 2002;
Suzuki et al, 2002). In the present study, patients with advanced
stages of colorectal cancer were immunised with up to four
peptides identified in pre-vaccination measurement of peptide-
specific CTL precursors to evaluate the toxicities and responses to
CTL precursor-oriented peptide vaccination.
MATERIALS AND METHODS
Patients and eligibility criteria
The study protocol was approved by the Institutional Ethical
Review Boards of Hokkaido University and Kurume University,
respectively. Complete written informed consent was obtained
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lfrom all of patients at the time of enrolment. According to the
protocol, patients were required to be HLA-A24 positive, and to
have a histologically confirmed lesion of colorectal carcinoma.
Eligibility criteria included an age of 85 years or less, serum
creatinine of less than 1.4mgdl
 1, bilirubin of less than 1.5mgdl
 1,
a platelet count of 100000ml
 1 or more, haemoglobin of 8.0gdl
 1
or more, and total WBC of 3000ml
 1 or more. Hepatitis B surface
antigen, Hepatitis C antigen, and human immunodeficiency virus
(HIV) were required to be negative. The patients, who had been
untreated for at least 4 weeks before the study, had an Eastern
Cooperative Oncology Group performance status of 0–2. The
treatment was carried out at the First Department of Surgery,
Hokkaido University School of Medicine (patients 1–9) and the
Department of Surgery, Kurume University School of Medicine
(patient 10) from November 2000 through April 2002. All
immunological analyses were carried out at the Department of
Immunology, Kurume University School of Medicine.
Screening of peptide-specific CTL precursors
A volume of 30ml of peripheral blood was obtained pre- and post-
(3rd, 6th, and 9th) vaccination, and PBMCs were isolated by means
of Ficoll–Conray density gradient centrifugation, as reported
previously (Miyagi et al, 2001). A previously reported method was
used to detect peptide-specific CTL precursors in PBMCs (Hida
et al, 2002; Suzuki et al, 2002). Briefly, PBMCs (1 10
5cellswell
 1)
were incubated with 10mM of a peptide in wells of u-bottom-type
96-well microculture plates (Nunc, Roskilde, Denmark) in 200mlo f
culture medium. The culture medium consisted of 45% RPMI-1640
medium, 45% AIM-V
s medium (GIBCO BRL), 10% FCS,
100Uml
 1 of interleukin (IL)-2, and 0.1mM MEM nonessential
amino-acid solution (GIBCO BRL). Every 3 days, half of the
medium was removed and replaced with new medium containing a
corresponding peptide (20mM). The assay was performed in
quadruplicate. After a 12-day incubation, the cultured cells in
one well were divided into four wells, two of which were used for
corresponding peptide-pulsed C1R-A2402 cells, and the other two
of which were used for HIV peptide (RYLRQQLLGI)-pulsed C1R-
A2402 cells. The HLA-A24-binding HIV peptide was used as a
negative control. After an 18-h incubation period, the supernatants
were collected and the level of interferon (IFN)-g was determined
by enzyme-linked immunosorbent assay (ELISA) (limit of
sensitivity: 10pgml
 1). The background response to HIV pep-
tide-pulsed C1R-A2402 cells was subtracted from the value.
Assessment of peptide-specific CTL precursors was performed
based on two parameters, the P-value by the Student’s t-test and
IFN-g production, as described in legends of Tables 2 and 4.
According to the results of this test, up to four positive peptides
were selected for each patient, utilised in a skin test, and then, if
negative, injected as a vaccination. The screening of peptide-
specific CTL precursors was performed by the same method after
the 6th vaccination to evaluate the effects of immunisation.
Peptides and vaccination
The peptides utilised in the present study were prepared under
conditions of Good Manufacturing Practice using a Multiple
Peptide System (San Diego, CA, USA). Montanide ISA-51, an
incomplete adjuvant, was manufactured by Seppic, Inc (Franklin
Lakes, NJ, USA). The peptides were supplied in vials containing
3mgml
 1 sterile solution for injection. A 3mg portion of peptide
with sterile saline was added in a 1:1 volume to Montanide ISA-51,
then mixed in a Vortex mixer (Fisher, Inc, Alameda, CA, USA).
The resulting emulsion was injected subcutaneously into the lateral
thigh using a glass syringe. Patients were vaccinated every 14 days
for a total of three injections to measure the toxicity. For the
patients with no toxicity, the vaccinations were repeated biweekly
up to 15 times with informed consent from each patient.
Delayed-type hypersensitivity (DTH) skin test
Skin tests were performed using 50mg of each peptide injected
intradermally in a volume of 100ml using a tuberculin syringe and
a 27-gauge needle. Saline was a negative control for assessment of
DTH. At least 7mm of induration or erythema read 48h after
injection was needed to score the skin test as positive (Nestle et al,
1998).
Assay of cytotoxicity
Cytotoxic activity was measured using a standard 6-h
51Cr-release
assay (Gomi et al, 1999; Miyagi et al, 2001). Cryopreserved PBMCs
were thawed and cultured in the medium consisting of 45% RPMI-
1640 medium, 45% AIM-V
s medium (GIBCO BRL), 10% FCS,
100Uml
 1 of IL-2, and 0.1mM MEM nonessential amino-acid
solution (GIBCO BRL). On the 14th day of culture, the cells were
harvested and served for the assay. To avoid the bias of bioassays,
PBMCs harvested at different times from a single patient were
thawed at the same time. SW620 (HLA-A24
þ, colon adenocarci-
noma), COLO201 (HLA-A24
 , colon adenocarcinoma), and PHA-
blastoid T cells (HLA-A24
þ) were used as target cells
(1 10
3well
 1), and 50-fold unlabelled K562 cells were added into
wells to decrease nonspecific killing activity.
Purification of CD8
þ or CD4
þ T cells
CD8
þ or CD4
þ T cells were positively isolated from peptide-
stimulated PBMCs using the CD8 Positive Isolation Kit (DYNAL,
Oslo, Norway) or the CD4 Positive Isolation Kit (DYNAL)
according to the manufacturer’s instructions. In both cases, the
percentage of purified CD8
þ or CD4
þ T cells was more than 90%
(data not shown).
Kinetics of peptide-specific CTL precursors
To detect the kinetics of peptide-specific CTL precursor frequency
in patient 1, PBMCs from before and after vaccination were
incubated at 100 cells per well of a 96-well u-bottom microculture
plate in the presence of feeder cells without the peptides. Cells
from each well were harvested on the 14th day of culture and tested
for their ability to produce IFN-g by recognition of peptide-pulsed
CIR-A2402 cells in duplicate assay. The well was considered
positive if it contained effector cells producing much higher than
100pgml
 1 and also statistically significant levels (Po0.05 by the
Student’s t-test) of IFN-g in response to CIR-A2402 cells preloaded
with a corresponding peptide as compared with those in response
to the HIV peptide-pulsed CIR-A2402 cells.
Detection of serum immunoglobulin G (IgG) levels
An ELISA was used to detect the serum IgG levels specific to the
peptides administered, as reported previously (Miyagi et al, 2001).
Briefly, the peptide (20mgwell
 1)-immobilised plate was blocked
with Block Ace (Yukijirushi, Tokyo, Japan), washed, and
100mlwell
 1 of serum samples diluted with 0.05% Tween 20-Block
Ace were added to the plate. After a 2-h incubation, the plate was
washed and further incubated for 2h with an 1:1000-diluted rabbit
anti-human IgG (DAKO, Glostrup, Denmark). The plate was
washed, after which 100ml of 1:100-diluted goat anti-rabbit Ig-
conjugated horseradish peroxidase-dextran polymer (En Vision,
DAKO) was added to each well, and the plate was incubated for
40min. After washing, 100mlwell
 1 of tetramethyl-benzidine
substrate solution (KPL, Guildford, UK) was added, and the
reaction was stopped by the addition of 1 M phosphoric acid. To
estimate peptide-specific IgG levels, the optical density values of
each sample were compared with those of serially diluted standard
samples, and the values are shown as the optical density. The
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lspecificity of the ELISA was tested as follows. Serum samples
(1:100 diluted) were incubated in wells precoated with corre-
sponding or irreverent peptides to absorb the peptide-specific IgG.
After a 2-h incubation at room temperature, samples were
transferred to new wells precoated with the sample peptide used
in the first absorption, and this protocol was repeated for a total of
three times. The samples were then subjected to peptide-specific
IgG ELISA.
Evaluation of treatment response
All known sites of disease were evaluated by CT-scan or X-ray
examination pre- and post-vaccinations (the 3rd, 6th, 9th, and
12th). Patients were assigned a response category according to the
response evaluation criteria in solid tumours, a revised version of
the WHO criteria published in the WHO Handbook for reporting
results of cancer treatment in June 1999.
RESULTS
Demographics of the patients
In all, 10 patients with advanced colorectal carcinomas were
enroled in this phase I study. Demographic details of the patients
are shown in Table 1. The median patient age was 67 years (range
28–78). All patients had liver, lung, peritoneum, or lymph node
metastases. All patients underwent surgical resection of the
primary lesion; nine had failed previous chemotherapy. All 10
patients completed the first three vaccinations within the protocol
under informed consent, and all of them received more vaccina-
tions (6–15) under additional informed consent.
Screening of peptide-specific CTL precursors
All tumour-related antigens were identified by screening of a
cDNA library from tumour cells using tumour-reactive CTLs. The
peptides used for this study have the potential to induce HLA-A24-
restricted and tumour-specific CTL activity in PBMCs of HLA-
A24
þ cancer patients (Kikuchi et al, 1999; Yang et al, 1999; Gomi
et al, 1999; Harashima et al, 2000; Kawano et al, 2000; Nakao et al,
2000; Nishizaka et al, 2000). Pre-vaccination PBMCs were provided
for screening of the CTL precursors reactive to the 14 candidate
peptides, followed by selection of peptides based on evaluation of
the results with the criteria shown in Table 2. The assay was
performed in quadruplicate. After a 12-day incubation, the
cultured cells in one well were separated into four wells, two of
which were used for corresponding peptide-pulsed C1R-A2402
cells, and the other two of which were used for HIV peptide-pulsed
C1R-A2402 cells. The HLA-A24-binding HIV peptide was used
as a negative control. The assessment of peptide-specific CTL
Table 1 Patient characteristics
Patient Age Sex Primary site Metastasis site Previous treatment
a P.S.
b No. of vaccination received
c
1 67 M Transverse colon Liver, para-aortic lymph node S. C 0 15
2 38 F Transverse colon Liver, peritoneum (intrapelvic) S. C 0 12
3 67 M Ascending colon Lung, liver S. C 1 6
4 78 M Rectum Liver S. C. M 0 10
5 70 F Sigmoid colon Lung, liver S. C 1 11
6 72 M Rectum Liver S 1 10
7 67 M Sigmoid colon Lung S. C 0 8
8 44 M Sigmoid colon Lung, liver S. C 0 6
9 46 M Ascending colon Peritoneum (intrapelvic) S. C 0 6
10 28 F Sigmoid colon Peritoneum (intrapelvic) S. C 1 8
aS ¼ surgery; C ¼ chemotherapy; M ¼ percutaneous microwave coagulation therapy.
bP.S. ¼ performance status by ECOG score.
cThe initial protocol consisted of three
vaccinations; additional vaccinations were subsequently performed to patients who showed a favourable clinical course after they provided further informed consent.
Table 2 Pre-vaccination screening of peptide-specific CTL precursors
Patients
Peptide Sequence 1 2 3 4 5 6 7 8 9 10 Positive case Vaccinated case
SART1 690 EYRGFTQDF JA JAA 2/10 2/10
SART2 93 DYSARWNEI JAB 1/10 1/10
SART2 161 AYDFLYNYL JA JAA 2/10 2/10
SART2 899 SYTRLFLIL KB 1/10 0/10
SART3 109 VYDYNCHVDL JA JB JC JC JA JA 6/10 6/10
SART3 315 AYIDFEMKI JC JC 2/10 2/10
CyB 84 KFHRVIKDF KA 1/10 0/10
CyB 91 DFMIQGGDF JA JA JC JA 4/10 4/10
lck 208 HYTNASDGL JC JA JA JC JC JB JAAA 7/10 7/10
lck 488 TFDYLRSVL JAB JAAAA JAB JA 4/10 4/10
lck 488 DYLRSVLEDF JA JA JAA 3/10 3/10
ART1 170 EYCLKFTKL KB KA KA KAA 4/10 0/10
ART4 13 AFLRHAAL KC 1/10 0/10
ART4 75 DYPSLSATDI JA JB 2/10 2/10
White circles indicate that the peptide was positive for the CTL precursor induction assay and was injected. Black circles indicate that the peptide was positive for the CTL
precursor induction assay but was not administrated due to immediate-type hypersensitivity by skin test. The assay was performed in quadruplicate and the background response
to the HIV peptide was subtracted from the value. The result was evaluated by the following criteria: A, Po0.05 and IFN-g production 450pgml
 1;B ,Po0.05 and 50pgml
 1
4IFN-g production 425pgml
 1: C, 0.05oPo0.1 and IFN-g production 425pgml
 1. The classification is shown by letters of the alphabet, and each character represents the
results of each well. For example, ABC means that three wells were judged as A, B, and C, and one well was negative.
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lprecursors was performed based on two parameters, the P-value by
the Student’s t-test and IFN-g production, as shown in the table
legend. When these peptides were found to induce immediate-type
hypersensitivity by a skin test, a fifth peptide was vaccinated if it
proved negative in the skin test. SART2899, CyB91, ART1170, and
ART413 were positive for immediate-type hypersensitivity in all
patients tested and were not injected at all. As a result, five patients
were injected with four peptides, three patients with three peptides,
and two with two peptides. The vaccinated peptides for each
patient are shown in Table 2. It is noteworthy that the profiles of
the vaccinated peptides varied greatly among the 10 patients.
Toxicities
All 10 patients were evaluated for toxicity; the overall toxicities are
shown in Table 3. The vaccinations were generally well-tolerated,
but almost all patients (eight out of 10) had grade I or II local
redness and swelling at the injection sites. Fever with mild flu-like
symptoms was observed in four patients (grade I or grade II),
although this symptom was transient and no medication was
needed. Grade I fatigue or nausea was observed in two patients,
and grade I anorexia, diarrhoea, or vomiting was observed in one.
No vaccine-related grade III or IV toxicity was observed (data not
shown). There was no clinical evidence of an autoimmune reaction
as determined by symptoms, physical examination, or laboratory
test.
Cellular immune responses
Post-vaccination (6th) PBMCs showed increased amounts of
peptide-specific IFN-g production compared to pre-vaccination
PBMCs in five out of 10 patients (1, 2, 5, 6, and 10), as described in
Table 4. Representative results of patients 1 and 2 are shown in
Figure 1A. In patients 1 and 2, CTL response to the lck208 was
apparently induced after the 6th vaccination. In five other patients,
peptide-specific CTL response decreased. We further tested the
reactivity of purified CD4
þ or CD8
þ T cells in response to the
administered peptides. The pre- or post-6th vaccination PBMCs
from patient 2 were in vitro stimulated, and purified CD4
þ or
CD8
þ T cells were tested for their reactivity to the SART3109
peptide-pulsed C1R-A2402 cells. As shown in Figure 1B, purified
CD8
þ T cells from the post-vaccination PBMCs of patient 2
produced IFN-g in an antigen-specific manner, although no
definite IFN-g production specific to the SART3109 peptide was
observed when unseparated post-6th PBMCs from patient 2 were
used (Figure 1A). Purified CD4
þ T cells failed to produce IFN-g in
a peptide-specific manner. On the other hand, no peptide-specific
IL-4 production was observed in the case with purified CD8
þ or
CD4
þ T cells (data not shown).
We next examined cytotoxicity of pre- and post- (3rd, 6th, and
9th) vaccination PBMCs from eight patients against SW620 (HLA-
A24
þ colon tumour cells), COLO201 cells (HLA-A24
  colon
tumour cells), and PHA-activated T cells (HLA-A24
þ) (Figure 2).
Tumour-related antigens from which all peptides used in this
study were derived are nonmutated self-antigens overexpressed in
tumour cells, including SW620 and COLO201 (Shichijo et al, 1998;
Yang et al, 1999; Gomi et al, 1999; Harashima et al, 2000; Kawano
Table 3 Toxicities associated with the peptide vaccination
Grade
a
Toxicities I II Total
Anorexia 1 1
Dermatologic 7 1 8
Diarrhoea 1 1
Fatigue 2 2
Fever 2 2 4
Nausea 2 2
Vomiting 1 1
aToxicities are based on the NIH Common Toxicity Criteria.
Figure 1 Assay of peptide-specific CTL precursors. (A) Pre- and post-
(6th) vaccination PBMCs were provided for screening of reactivity to each
of the 14 peptides listed in Table 2 in the quadruplicate assays.
Representative results of patients 1 and 2 are shown in this figure. The
peptide-stimulated PBMCs were cultured with C1R-A2402 cells that were
preloaded with the corresponding peptide (open bar) or the HIV peptide
(closed bar). The level of IFN-g in the supernatant was determined by
ELISA. The result was evaluated by the classification shown in the legend of
Table 4. Each alphabet character represents the result of each well. (B)
Pre- and post- (6th) vaccination PBMCs from patient 2 were stimulated in
vitro with the SART3109 peptide. The peptide-stimulated PBMCs were
harvested, and positively isolated CD4
þ or CD8
þ T cells were cultured in
triplicate with C1R-A2402 cells that were preloaded with the SART3109
peptide (open bar) or the HIV peptide (closed bar). The level of IFN-g in
the supernatant was determined by ELISA. *Statistically significant at
Po0.05.
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let al, 2000; Nakao et al, 2000; Nishizaka et al, 2000). As shown in
four cases of patients 2, 3, 7, and 9, cytotoxicity against HLA-A24
þ
SW620 increased after peptide vaccination compared to that
against HLA-A24
  COLO201. In the other four cases, no definite
increase in cytotoxicity was observed after the peptide vaccination.
No cytotoxicity against HLA-A24
þ PHA-blastoid T cells was
detected in any case. These results indicate that the peptide
vaccination resulted in augmented CTL activity in four out of eight
patients.
Serum IgG specific to peptides
No IgG reactive to any of the vaccinated peptides was detected
in pre-vaccination sera from any of the 10 patients (Table 4).
Significant levels of anti-peptide IgG reactive to SART3- or
lck-derived peptides became detectable in the post-vaccination
sera of seven patients. Detail results are shown in Figure 3.
In patient 1, IgGs reactive to the lck208 and the lck488 peptides were
induced after the 6th and 9th vaccinations, respectively (Figure 3A).
A similar result was observed in six other patients (Figure 3B).
It is noteworthy that three patients who showed strong peptide-
specific CTL response (criteria Ar) after the peptide vaccination
were also positive for antipeptide IgG to the corresponding
peptides (patient 1 for lck208 and lck488, patient 6 for SART3109,
and patient 10 for SART3315). In addition, the IgG response to
the lck208 peptide in post-vaccination sera of patient 1 was
neutralised by absorption with a corresponding peptide, but
not with the lck408 peptide, whereas the opposite was observed in
the case of the IgG response to the lck488 peptide (Figure 3C). This
peptide-specific absorption demonstrates the validity of the ELISA
system.
DTH skin test
No DTH reaction against peptides was observed before vaccination
in any patient, while peptide-specific DTH reactions were observed
Table 4 Summary of response to the peptide vaccination
Peptide-specific CTL
a Ab to peptide DTH
Clinical response/
Patient Peptide Pre Post Pre Post
b Pre Post
b Time to progression (months)
1 SART3 109 A C      7mm (9) PR/7o
lck 208 C ArArA   + (6)   10mm (6)
lck 488 A Ar   + (9)   10mm (6)
2 SART3 109 B    + (6)    SD/7
lck 208 A AAAA       
lck 486 AB A   + (9)   
3 CyB 91 A C        PD/3
lck 488 A A       
ART4 75 A         
4 CyB 91 A          PD/3
lck 208 A C      7mm (3)
lck 486 AAAA C      7mm (3)
lck 488 AA        7mm (3)
5 SART3 109 C ArB        PD/4
lck 208 C A   + (9)   
6 SART3 109 C ArBC   + (6)    PD/3
ART4 75 B B       
7 SART3 109 A A   + (6)   10mm (3) PD/4
SART3 315 C         
CyB 91 C         
lck 208 C C       
8 SART1 690 A          PD/4
SART2 93 AB         
SART2 161 A C       
lck 208 B         
9 SART1 690 AA          PD/4
SART2 161 AA         
SART3 109 A         
lck 486 AB C   +(6)   
10 SART3 315 C ArAA   +(6)    PD/3
CyB 91 A         
lck 208 AAA         
lck 486 AA         
aThe CTL precursor induction assay was performed in quadruplicate, and the background response to the HIV peptide was subtracted from the value. The result was evaluated
by the following criteria: Ar (armed response), Po0.1 and IFN-g production 4500pgml
 1;A ,Po0.05 and IFN-g production 450pgml
 1:B ,Po0.05 and 50pgml
 1 4IFN-g
production 425pgml
 1; C, 0.05oPo0.1 and IFN-g production 425pgml
 1. The classification is shown by letters of the alphabet, and each character represents the results of
each well. For example, ArBC means that three wells were judged as Ar, B, and C, and one well was negative.
bThe number in the parenthesis represents the vaccination when
anti-peptide IgG or DTH was detected for the first time.
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lin three patients after the peptide vaccination (Table 4). In patient
1, DTH reactions to lck208 and lck488 were observed after the 6th
vaccination, and DTH against SART3109 became detectable after
the 9th vaccination. Patient 4 exhibited a DTH reaction against
lck208, lck486, and lck488 after the 3rd vaccination. Patient 7
exhibited a DTH reaction against SART3109 after the 3rd
vaccination.
Clinical results
The clinical responses of each patient are summarised in
Table 4. CT scans of patient 1 pre- and post-vaccination are
shown in Figure 4A. In all, 48% regression (27–14mm) of
liver metastasis was observed in patient 1. This patient had para-
aortic lymph node metastasis at a diameter of less than 20mm; it
showed no change after the peptide vaccination (data not shown).
Because his clinical response was considered a partial response
(PR), this patient was analysed more in detail. The kinetic analysis
of tumour cell lysis in patient 1 indicates that increased CTL
activity to the SW620 cells became detectable in post-vaccination
PBMCs (Figure 4B). The cytotoxicity against lck208 peptide-loaded
CIR-A2402 cells became significant after the 3rd and 6th
vaccinations (Figure 4C). While no peptide-specific IFN-g
production was detected in any of the 96 wells containing
100cellswell
 1 of pre-vaccination PBMCs, SART3109-specific
IFN-g production was detected in two, two, and four wells among
96 wells containing post-vaccination (3rd, 6th, and 9th) PBMCs,
respectively (Figure 4D). Production of lck208-specific IFN-g
production was detectable in three and four wells among 96 wells
containing the 6th and 9th vaccination PBMCs, while lck488-
specific IFN-g production could be observed in one and two wells
among 96 wells containing the 6th- and 9th-vaccination PBMCs,
respectively. The patient has subsequently been treated only by
vaccination (SART3109, lck208, and lck488) for 7 months as an
outpatient, and is still doing well. Patient 2 had intrapelvic
metastasis, and the disease has remained stable (s.d.) for 6 months.
The eight other patients showed progressive disease (PD) 2–4
months after starting the vaccinations, although all have been
treated as outpatients and their quality of life has been evaluated as
quite high.
DISCUSSION
Patients undergoing this regimen received 3mg of peptides
biweekly for up to four peptides. All of the peptides used were
derived from nonmutated self-antigens involved in cellular
proliferation (Kikuchi et al, 1999; Gomi et al, 1999; Yang et al,
1999; Harashima et al, 2000; Kawano et al, 2000; Nakao et al, 2000;
Nishizaka et al, 2000). However, there was no grade III or IV
adverse effect, which is consistent with previous observations in
studies of peptide-based vaccinations. Most of the patients
received the vaccination as outpatients, and the performance
status remained very good throughout the treatment periods.
Therefore, in terms of safety, this regimen of CTL precursor-
oriented peptide vaccine could be recommended as a cancer
vaccine suitable for further clinical trials.
Another aim of our study was to assess the clinical response to
the vaccination. In our limited number of case, we observed one
PR and one s.d. continuing for more than 6 months. Both of these
cases were treated with three kinds of SART3- and lck-derived
Figure 2 Cytotoxicity before and after the peptide vaccination. Pre- and post-vaccination PBMCs from eight patients were incubated for 14 days with IL-2
alone without any peptides in culture, followed by measurement of cytotoxicity against SW620 cells (HLA-A24
þ colon cancer cell line), COLO201 cells
(HLA-A24
  colon cancer cell line), and PHA-activated T cells (HLA-A24
þ) by a 6-h
51Cr-release assay at an E/T ratio of 40/1. The assay was performed in
triplicate, and the mean and s.d. are shown. *Statistically significant at Po0.05.
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constitute a promising vaccine strategy for advanced colorectal
carcinomas, thus encouraging us to plan a phase II trial utilising
these peptides.
Vaccination-induced immunity was evaluated in this study by
several different methods, including IFN-g production in response
to peptides, a standard 6-h
51Cr-release assay, measurement of
antipeptide antibody, and DTH responses. An elevated immune
response to lck208 and lck488 was detected in post-vaccination
PBMCs by all of the methods used in the samples of patient 1, who
showed PR. This patient’s PBMCs also reacted to the SART3109
peptide, as measured by frequency analysis of cellular responses to
peptides (Figure 4D) and also by DTH test (Table 4). These results
indicate that the patient’s PBMCs reacted to all three vaccinated
peptides after the peptide vaccination. Post-vaccination PBMCs
from patient 2, who had a long s.d., responded to lck208 peptide
alone, and the post-vaccination sera became positive for both the
SART3109 and lck486 peptides, although no DTH response was
observed (Table 4). Besides patient 1, positive DTH response was
observed in only two patients (4 and 7), with PD, but their post-
vaccination PBMCs showed no increase in cellular responses to the
administered peptides. On the other hand, besides patients 1 and 2,
IgG reactive to the administered peptides became detectable in the
post-vaccination sera of five other patients (5, 6, 7, 9, and 10)
with PD. Although the post-vaccination PBMCs of patients 6 and
10 showed an increase in cellular responses to SART3109
and SART3315, respectively, no augmentation of peptide-specific
cellular response was observed in other cases. Neither a cellular
nor humoral immune response to administered peptides was
detectable in the remaining two patients (3 and 8), who also
had PD. These results suggest that vaccination-induced immunity
varies considerably among patients. However, we recently reported
that the in vivo induction of IgG reactive to administered peptides
is positively correlated with clinical response or the survival
of patients with prostate, lung, gastric, or gynaecological
cancer (Mine et al, 2003; Noguchi et al, 2003; Sato et al, 2003;
Tsuda et al, 2004). This may be the case with patients 1 and 2,
who showed PR and s.d., respectively, because IgGs reactive to two
different peptides were induced only in these two patients. We
have no clear answer regarding the role of peptide-specific IgG in
antitumour immune response, and are now grappling with this
theme.
In addressing the mechanism for peptide-specific IgG induction
after peptide vaccination, one possibility is that 9-mer or 10-mer
peptide-recognizing CD4
þ T cells were involved in this phenom-
enon. In general, in vivo generation of antigen-specific IgG
requires a cytokine from helper T cells (Parker, 1993). Although
peptides binding to MHC class II molecules have been suggested to
be 12–25 amino acids in length, the core sites anchored to MHC
class II molecules are sufficient even at a length of about nine
amino acids (Rammensee et al, 1995). Indeed, we recently
observed that peptide vaccination with a 9-mer peptide could
induce peptide-specific and HLA-DR-restricted CD4
þ T cells in
vivo (Harada et al, 2004). CD4
þ T-cell help is required during the
generation and maintenance of effective anti-tumour CD8
þ T cell-
mediated immunity. The requirement of CD4
þ T-cell help to
initiate and sustain a CD8
þ T-cell response has been well
established and has led to the development of antitumour vaccines
that attempt to induce both T-cell subsets (Knutson et al, 2001).
The in vivo induction of IgG reactive to administered peptides may
be indirect evidence of the involvement of CD4
þ T lymphocytes.
We recently developed a culture system to evaluate CTL
precursors against many peptides using a limited number of
PBMCs from cancer patients (Hida et al., 2002); the same culture
system was applied to this study. The main reason why we assessed
peptide-specific CTL precursors based on two parameters, the P-
value and IFN-g production, was that the levels of IFN-g produced
by peptide-specific CTLs varied among quadruplicate wells. This
finding might be due to the small number of cells (10
5cellswell
 1)
that were initially placed in each well. It is possible that one well
may have contained peptide-specific CTL precursors, whereas
another may have contained none. We concluded that each well
should be individually estimated to screen for the presence of
peptide-specific CTL precursors.
Recent reports revealed that a Th2 response is predominant in
cancer patients (Pellegrini et al, 1996; Vita et al, 1999; Sheu et al,
2001). Therefore, we examined the level of IL-4 during peptide
stimulation in vitro, but the level of IL-4 production was generally
low, and no peptide-specific IL-4 production was observed. In
contrast, the level of IFN-g production was constantly substantial.
Probably, the in vitro culture of PBMCs in the presence of IL-2
could preferentially activate natural killer cells, and natural killer
cell-derived IFN-g might provide an optimal condition for Th1
type cells.
In conclusion, vaccination of colorectal cancer patients with
peptides by the CTL precursor-oriented method was a well-
tolerated outpatient treatment and induced antigen-specific
immunity as well as a clinical response. Even though only a small
number of selected patients were treated, the encouraging clinical
response demands further studies of CTL precursor-oriented
vaccine in other human cancers.
Figure 3 IgG reactive to the vaccinated peptides. (A) Pre- and post-
vaccination sera from patient 1 were serially diluted and the levels of IgGs
reactive to three administered peptides were determined by ELISA. (B)
Pre- and post-vaccination sera from patients 2, 5, 6, 7, 9, and 10 were
serially diluted and the levels of IgGs reactive to corresponding peptides
were determined by ELISA. (C) Diluted sera of patient 1 after the 9th
vaccination were cultured in the indicated peptide-coated wells and the
levels of IgGs reactive to corresponding peptides were determined by
ELISA. *Statistically significant at Po0.05.
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